Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients
28/05/2026 06:32
BRIEF-Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients May 28 (Reuters) - Ipsen SA IPN.PA:
IQIRVO SHOWS CLINICALLY MEANINGFUL FATIGUE IMPROVEMENTS IN MODERATE-TO-SEVERE PBC PATIENTS
IQIRVO ACHIEVES 59% ALP NORMALIZATION AT 6 MONTHS IN REAL-WORLD PBC ANALYSIS
ELFINITY PHASE IV INTERIM ANALYSIS SHOWS REAL-WORLD EFFECTIVENESS AND TOLERABILITY OF IQIRVO
Source text: ID:nGNX7VS7yh
Further company coverage: IPN.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587696600;;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients